Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562738 | 0.96 | ALOX5 (0.45) | TAS2R14ALOX5PTGESALDH1A1SLC16A3 | |
| SCHEMBL3555950 | 0.85 | TAS2R14 (0.46) | TAS2R14ALOX5PTGESALDH1A1SLC16A3 | |
| SCHEMBL3560865 | 0.84 | ALOX5 (0.57) | TAS2R14ALOX5PTGESALDH1A1RARB | |
| SCHEMBL3554681 | 0.84 | SLC16A3 (0.55) | ALOX5PTGESSLC16A3RARBL3MBTL1 | |
| SCHEMBL3555861 | 0.82 | SLC16A3 (0.44) | ALOX5PTGESHTTSLC16A3RARB | |
| SCHEMBL3563720 | 0.82 | ALOX5 (0.45) | ALOX5PTGESALDH1A1SLC16A3 | |
| SCHEMBL3564284 | 0.82 | ALOX5 (0.58) | TAS2R14ALOX5PTGESRARBL3MBTL1 | |
| SCHEMBL3557378 | 0.82 | ALOX5 (0.58) | TAS2R14ALOX5PTGESL3MBTL1 | |
| SCHEMBL3553576 | 0.82 | ALOX5 (0.47) | TAS2R14ALOX5PTGESALDH1A1SLC16A3 | |
| SCHEMBL3554627 | 0.81 | ALOX5 (0.57) | TAS2R14ALOX5PTGESL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | TAS2R14 3203/4885ALOX5 101/4885PTGES 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.